Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00061087 · ClinicalTrials.gov registry record · Phase 2

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

A Phase 2 study of ADHD and Opioid-Related Disorders, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
115
Enrollment target
1
Study location

NCT00061087 is a Phase 2 study of ADHD and Opioid-Related Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 115 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00061087, a Phase 2 study of ADHD and Opioid-Related Disorders, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
115 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD) in methadone patients.

Interventions

  • OTHER Placebo
  • DRUG Methylphenidate
  • DRUG Bupropion

Study Locations (1)

New York

  • Research Foundation for Mental Hygiene, Inc. - New York

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 1998-02
Est. Completion 2004-10
Phase Phase 2

What the Registry Record Tells You About NCT00061087

The ClinicalTrials.gov registry entry for NCT00061087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (39% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with ADHD appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00061087 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00061087 about?

NCT00061087 is a clinical study titled "Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1". The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD) in methadone patients.

What is the current status of trial NCT00061087?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 1998-02. Estimated completion is 2004-10.

What conditions does trial NCT00061087 study?

This clinical trial studies the following conditions: ADHD, Opioid-Related Disorders, Cocaine Dependence.

What interventions are being tested in trial NCT00061087?

The interventions under investigation include: Placebo (OTHER), Methylphenidate (DRUG), Bupropion (DRUG).

Who is sponsoring clinical trial NCT00061087?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00061087 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.